Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review.

Abstract excerpt

Mutations in the epidermal growth factor receptor (EGFR) are drivers of a subset of lung cancers. In recent years, the treatment of non-small cell lung cancer (NSCLC), especially with EGFR inhibitors, has made rapid progress, and the median progression-free survival (PFS) of patients with EGFR gene-sensitive mutations has been significantly prolonged. However, the response effect of some uncommon EGFR mutations...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenocarcinoma of Lung
• Share to Aged